Physician profile
Steven Michael Lowry
NPI 1285637223
$9,261.50
in general payments reported to CMS, 2019-2025
49 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $1,170 · 2021: $1,198 · 2022: $1,351 · 2023: $1,457 · 2024: $1,283 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,631.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $998.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $710.62 | 2019-2025 | |
| Pfizer INC. | $652.58 | 2019-2025 | |
| Lilly USA, LLC | $510.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $492.32 | 2019-2025 | Repatha, Evenity, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.80 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $383.74 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $256.71 | 2019-2025 | Zoryve, Livalo |
| Abbott Laboratories | $253.34 | 2019-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $235.13 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $231.79 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $213.40 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.33 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $202.26 | 2019-2025 | Gardasil 9, Lagevrio, Vaqta |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.